DUBLIN--(BUSINESS WIRE)--The "Sodium Dependent Glucose Transporter 1 (SGLT1) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Sodium Dependent ...
The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...
In a recent rat study, scientists found that blocking both SGLT1 and SGLT2 worked better than blocking SGLT2 alone for ...
“SONATA-HCM will evaluate the efficacy of sotagliflozin, a dual SGLT2 and SGLT1 inhibitor, on symptoms, function, and other patient-reported outcomes, as well as safety in patients with symptomatic ...
Sotagliflozin (Inpefa) had a 23% risk reduction for major adverse cardiovascular events in high-risk patients with type 2 diabetes and chronic kidney disease. The dual SGLT1/2 inhibitor yielded a 32% ...
Christopher P. Cannon, MD, was one of the investigators on the SOLOIST trial, which led to the approval of sotagliflozin, the first dual sodium-glucose cotransporter-1 and -2 (SGLT1/2) inhibitor.
Earlier this year, empagliflozin (Jardiance) won FDA approval for a broader indication in heart failure across the spectrum of ejection fraction. As part of our review of the year's top stories, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback